Generex Biotechnology Corporatio (GNBT) 0.0133 $GNBT
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 20.00 (-0.81), ADMP: 6.50 (-0.01)
Generex Announces Participation in MedCannAccess® - CannScience Partnership on Non-Smoked Forms of Marijuana
PR Newswire - Wed Dec 17, 8:00AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced its participation in a MedCannAccess (www.MedCannAccess.com) partnership with CannScience Innovations Inc.
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/l6bhq9/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Bayer AG - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. - Thrombotargets Corporation - Diakron Pharmaceuticals, Inc. - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/l6bhq9/deep_vein
BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Generex Announces Collaboration on Medicinal Cannabis
PR Newswire - Tue Nov 18, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) to license the Company's proprietary RapidMist(TM) drug delivery technologies to CannScience Innovations Inc. (CannScience) for the delivery of medicinal cannabis derived products into the bloodstream through the buccal membrane.
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 16.96 (+0.66), BAX: 70.39 (+0.31), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), SVA: 5.05 (+0.06)
Generex Announces Presentation at the Society for Immunotherapy of Cancer Demonstrating that Induction of Antibody Response in Patients Receiving the AE37 Breast Cancer Vaccine Correlates with Reduced Relapse
PR Newswire - Tue Nov 11, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced a presentation showing that induction of an antibody response to the HER2 target of its AE37 cancer vaccine correlated with a reduction of relapse in breast cancer patients. The AE37 cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentation was part of the 29th Annual Meeting & Associated Programs of the Society for Immunotherapy of Cancer (SITC) (www.sitcancer.org) that was held November 6-9, 2014 in National Harbor, MD.
Global Breast Cancer Vaccine Clinical Trial Insight
M2 - Wed Oct 29, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2zwt4/global_breast) has announced the addition of the "Global Breast Cancer Vaccine Clinical Trial Insight" report to their offering. Cancer vaccines have emerged a viable option for treating multiple cancers which in the present day scenario do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defenses against the cancer while the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this highly profitable emerging field of preventing, treating, and potentially curing the cancer. In last few years, the peptide cancer vaccines have been demonstrating potential in clinical trials for the treatment of breast cancer. The high versatility and easy modification capabilities have made them widely acceptable among oncologists. They are sometimes developed to target over expressed receptors specific to the breast cancer cells. These vaccines stimulate a cancer patients' immune system to identify and eliminate breast cancer cells. Clinical trials have also shown the efficacy of peptide vaccines in shrinking breast cancer. This has encouraged the oncologists to develop better breast cancer vaccine for patients. The development and deciphering of underlying principle of breast cancer vaccine will improve significantly driven by technological advancement occurred in recent years. Innovative products developed in this way will decrease the development time and will also help in cost arbitrage. Without cost effectiveness it would be difficult for pharmaceutical companies to compete and occupy substantial share in breast cancer market. However, it is expected that the cost of these vaccines would be high at the time of introduction which will subsequently decrease due to availability of other vaccines in same category. It is most likely that the first breast cancer vaccines would be introduced in market in the next 3-5 years period. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the final stages of clinical trials which are supposed to clear the targeted end points. Global Breast Cancer Vaccine Clinical Trial Insight Report Highlight: - Global Breast Cancer Vaccine Market Overview - Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country - Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines - Detailed Clinical Insight on Breast Cancer Vaccine Pipeline: 35 Vaccines - Majority in PHASE-I Clinical Trial: 12 Vaccines - Highest Clinical Phase is PHASE-III: 2 Vaccines (NeuVax & OBI-822) Key Topics Covered: 1. Global Breast Cancer Vaccine Market Overview 2. Global Breast Cancer Vaccine Market Dynamics 3. Mechanism of Breast Cancer Vaccine 4. Personalized Cancer Vaccines: Progress & Possibilities 5. Global Breast Cancer Vaccine Market Future Prospects 6. Global Breast Cancer Vaccines Pipeline by Phase, Company & Country 7. Suspended & Discontinued Breast Cancer Vaccines Pipeline by Phase, Company & Country 8. Competitive Landscape - AlphaVax - Galena Biopharma - Generex Biotechnology - GlaxoSmithKline - Immune Design - Immunovaccine - Immunovative Therapies - Imugene - TapImmune - ViroMed For more information visit http://www.researchandmarkets.com/research/z2...bal_breast
IMDZ: 25.34 (+1.20), GALE: 1.68 (+0.06), GSK: 47.94 (+1.99)
Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons
PR Newswire - Mon Oct 27, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced two presentations demonstrating that the extent of the immunological response triggered by its novel proprietary cancer immunotherapeutic AE37 vaccine correlated with a reduction of relapse in breast cancer patients. The AE37 cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations are being made at the American College of Surgeons Clinical Congress 2014, being held October 26-30, 2014 in San Francisco, CA.
Generex / Antigen Express to Participate in 2014 BIO-Europe® Annual International Partnering Conference
PR Newswire - Thu Oct 23, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 2014 BIO-Europe® Annual International Partnering Conference being held November 3-5 in Frankfurt, Germany.
Generex Announces Publication of Ebola Vaccine White Paper by Antigen Express
PR Newswire - Tue Oct 21, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that its wholly owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has issued a white paper outlining the advantages of its Ii-Key technology in the development of an effective Ebola vaccine.
Generex Clarifies Utility of Antigen Express Technology for Potential Ebola Vaccine
PR Newswire - Tue Oct 07, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today responded to a recent article posted to the Seeking Alpha website (http://seekingalpha.com/article/2533015-with-ebola-looming-when-will-the-defense-department-get-around-to-generex) regarding the need for an Ebola vaccine and the importance of providing funding for small companies with technologies applicable to such an endeavor. Generex is the parent company of Antigen Express, Inc. (www.antigenexpress.com), which focuses on the development of synthetic peptide vaccines for significant unmet medical needs.
Generex hires Dr Lakshmi P. Kotra for buccal insulin enhancement project
M2 - Wed Oct 01, 6:12AM CDT
Drug delivery company Generex Biotechnology (Other OTC :GNBT) said on Tuesday that it has engaged Dr Lakshmi P. Kotra, B. Pharm(Hons), PhD to provide consultancy, expertise and assistance in the management of its buccal insulin enhancement project.
Generex Announces Engagement of Dr. Lakshmi P. Kotra for Buccal Insulin Enhancement Project
PR Newswire - Tue Sep 30, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it has engaged Dr. Lakshmi P. Kotra, B. Pharm.(Hons), Ph.D., as a consultant to the Company to provide expertise and assistance in the management of the Company's previously announced buccal insulin enhancement project. In this role, Dr. Kotra will work closely with the Company's Senior Scientific Advisor, Dr. James H. Anderson, Jr., MD, and Company management working to increase the insulin bioavailability of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes.
Generex Collaborates with University Health Network for Buccal Insulin Project
PR Newswire - Mon Sep 22, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it has entered into a collaboration with University Health Network (UHN) pursuant to which UHN's Centre for Molecular Design and Preformulations (CMDP) will spearhead the Company's buccal insulin refinement project. The goal of the project is to increase the insulin bioavailability of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. This research will ensure the product is more attractive to patients and prospective commercialization partners.
Generex / Antigen Express to Participate in BioPharm America(TM) 2014
PR Newswire - Wed Sep 03, 8:15AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 7th Annual International Partnering Conference BioPharm America(TM) 2014 being held September 22-24 in Boston. The conference is a significant business development forum for companies like Antigen Express, providing access to high-level executives and influential decision makers who attend the forum to liaise with key players in the industry, form partnerships, and evaluate emerging technologies. Antigen Express launched its strategic partnering program at the BIO International Convention in San Diego in June, 2014.
Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
PR Newswire - Wed Aug 06, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune response generated by AE37 and improved overall survival. The compound is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.84 (-0.01), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), NNVC: 2.97 (-0.05), SIGA: 1.95 (-0.01), JNJ: 99.62 (+1.18), OPK: 13.80 (-0.28), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015
M2 - Wed Jan 21, 5:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/qxt9lq/global_prostate) has announced the addition of the "Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015" report to their offering. Prostate cancer vaccine is a recent development which is more potent than presently available prostate cancer therapeutics in providing better medical care. Prophylactic nature of this vaccine makes it possible to prevent the future incidences of prostate cancer. Besides, it can also prevent the relapse, provides long- term immunity, decrease morbidity and mortality rates along with increasing longevity. Owing to these benefits offered by prostate cancer vaccines their acceptance is increasing among patients and physicians in recent years. It is expected that due competition and increased number of products in market will cause decrease in the price of prostate cancer vaccines in coming years. Prostate cancer vaccine utilizes different antigens like Prostate-Specific Membrane Antigen, Prostate-Specific Antigen (PSA) and Prostatic Acid Phosphatase (PAP) in pharmacological formulations. These antigens are isolated from the prostate tumor and injected into the body to activate the immune cells. They identify these antigens as non-self and begin to search and eliminate cancerous cells from body to prevent proliferation of cancerous cells. Highly specific nature causes elimination of cancerous cells in prostate while sparing normal cells leading to minimized side effects in patients. Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights: - Introduction to Prostate Cancer Vaccine - Mechanism of Prostate Cancer Vaccine - Global Prostate Cancer Vaccine Clinical Trial Insight by Company, Country & Phase - Global Prostate Cancer Vaccine Clinical Pipeline: 41 Vaccines - Majority Prostate Cancer Vaccine in Phase-II: 10 Vaccines - Marketed Prostate Cancer Vaccine: 1 (Provenge by Dendreon Corporation) Key Topics Covered: 1. Introduction to Prostate Cancer Vaccine 2. Mechanism of Prostate Cancer Vaccine 3. Global Prostate Cancer Vaccine Market Dynamics 4. Global Prostate Cancer Vaccine Market Outlook 5. Global Prostate Cancer Vaccine Market Future Prospects 6. Personalized Cancer Vaccine Market Opportunities 7. Global Prostate Cancer Vaccines Clinical Trial Insight by Company, Country & Phase 8. Marketed Prostate Cancer Vaccines by Company & Country 9. Suspended & Discontinued Prostate Cancer Vaccines in Clinical Trials 10. Competitive Landscape - Adamis Pharmaceuticals - Aduro BioTech - Bellicum Pharmaceuticals - CytoVac - Dendreon Corporation - Generex Biotechnology Corporation - Immunovaccine - Oncbiomune - Progenics - Sotio For more information visit http://www.researchandmarkets.com/research/qx...l_prostate
BLCM: 20.00 (-0.81), ADMP: 6.50 (-0.01)
Generex Announces Participation in MedCannAccess® - CannScience Partnership on Non-Smoked Forms of Marijuana
PR Newswire - Wed Dec 17, 8:00AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced its participation in a MedCannAccess (www.MedCannAccess.com) partnership with CannScience Innovations Inc.
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014
M2 - Thu Dec 11, 8:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/sbbrcj/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" report to their offering. H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H2, 2014" provides data on the H5N1 Infection (Avian Influenza) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on H5N1 Infection (Avian Influenza). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating H5N1 Infection (Avian Influenza). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Novartis AG - GlaxoSmithKline plc - Baxter International Inc. - Mitsubishi Tanabe Pharma Corporation - AstraZeneca PLC - Microgen Scientific Industrial Company for Immunobiological Medicines - Green Cross Holdings Corporation - Generex Biotechnology Corporation - Daiichi Sankyo Company, Limited - CSL Limited Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Mahidol University - National Hospital Organization Mie National Hospital - The Chemo-Sero-Therapeutic Research Institute - Clinical Research Center, National Hospital Organization - Queen Mary Hospital - Tohoku University Graduate School of Medicine, Department Of Surgery - Fraunhofer Center for Molecular Biotechnology - South East Asia Infectious Disease Clinical Research Network For more information visit http://www.researchandmarkets.com/research/sb..._infection
BAX: 70.39 (+0.31), AZN: 69.96 (+0.20), GSK: 47.94 (+1.99), NVS: 102.20 (-0.17)
Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/l6bhq9/deep_vein) has announced the addition of the "Deep Vein Thrombosis (DVT) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Deep Vein Thrombosis (DVT), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Deep Vein Thrombosis (DVT) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Deep Vein Thrombosis (DVT) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Generex Biotechnology Corporation - Bayer AG - Merrion Pharmaceuticals Plc - Regado Biosciences, Inc. - Thrombotargets Corporation - Diakron Pharmaceuticals, Inc. - Armetheon, Inc. For more information visit http://www.researchandmarkets.com/research/l6bhq9/deep_vein
BMY: 60.04 (+0.56), RGDO: 1.17 (+0.02)
Generex Announces Collaboration on Medicinal Cannabis
PR Newswire - Tue Nov 18, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that it has entered into a non-binding Letter of Intent (LOI) to license the Company's proprietary RapidMist(TM) drug delivery technologies to CannScience Innovations Inc. (CannScience) for the delivery of medicinal cannabis derived products into the bloodstream through the buccal membrane.
Global Biologic Therapeutics Market 2014-2018: Key Vendors are Amgen, F. Hoffmann-La Roche, Novo Nordisk and Sanofi
M2 - Mon Nov 17, 3:57AM CST
Research and Markets (http://www.researchandmarkets.com/research/tx4gv7/global_biologic) has announced the addition of the "Global Biologic Therapeutics Market 2014-2018" report to their offering. One key trend upcoming in this market is the emergence of targeted therapies, which are generally associated with better efficacy and safety compared to traditional drugs. Thus, these drugs are expected to increase patient compliance and fuel the market. According to the report, an aging population is one of the major drivers of the market. An increase in the aging population is expected to increase the population of patients suffering from a variety of diseases, and thereby drive the market. Further, the report states that the need for cold storage is one of the major challenges in the market. Cold storage increases the transportation and storage costs of the therapeutic products, thereby adding to the final cost of the products. The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Molecule Type 08. Geographical Segmentation 09. Buying Criteria 10. Global Protein Therapeutics Market 11. Global Vaccines Market 12. Global Cell Therapy Market 13. Market Growth Drivers 14. Drivers and their Impact 15. Market Challenges 16. Impact of Drivers and Challenges 17. Market Trends 18. Trends and their Impact 19. Competitive Scenario 20. Market Share Analysis 2013 21. Market Assessment of Major Biologic Therapeutics of Key Vendors 22. Key Vendor Analysis 23. Other Reports in this Series Companies Mentioned: - Abbvie - Amgen - AstraZeneca - Bavarian Nordic - Baxter International - Beijing Minhai Biotechnology - Bharat Biotech - Bharat Immunologicals and Biologicals - Bio Med - Biodel - Bristol-Myers Squibb - DiaVacs - Diamyd Medical - Dynavax Technologies - Eli Lilly - F. Hoffmann-La Roche - Generex Biotechnology - Hualan Biological Engineering - Imunoloski Zavod - Indian Immunologicals - JN International Medical - Janssen Pharmaceuticals - Sanofi - Serum Institute of India - Shenzhen Kangtai Biological Products - Sinovac Biotech - Tolerion - Vacunas Finlay - XOMA - Zydus Cadila - bioCSL For more information visit http://www.researchandmarkets.com/research/tx...l_biologic
DVAX: 16.96 (+0.66), BAX: 70.39 (+0.31), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), SVA: 5.05 (+0.06)
Generex Announces Presentation at the Society for Immunotherapy of Cancer Demonstrating that Induction of Antibody Response in Patients Receiving the AE37 Breast Cancer Vaccine Correlates with Reduced Relapse
PR Newswire - Tue Nov 11, 8:30AM CST
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced a presentation showing that induction of an antibody response to the HER2 target of its AE37 cancer vaccine correlated with a reduction of relapse in breast cancer patients. The AE37 cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentation was part of the 29th Annual Meeting & Associated Programs of the Society for Immunotherapy of Cancer (SITC) (www.sitcancer.org) that was held November 6-9, 2014 in National Harbor, MD.
Global Breast Cancer Vaccine Clinical Trial Insight
M2 - Wed Oct 29, 11:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2zwt4/global_breast) has announced the addition of the "Global Breast Cancer Vaccine Clinical Trial Insight" report to their offering. Cancer vaccines have emerged a viable option for treating multiple cancers which in the present day scenario do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body's natural defenses against the cancer while the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this highly profitable emerging field of preventing, treating, and potentially curing the cancer. In last few years, the peptide cancer vaccines have been demonstrating potential in clinical trials for the treatment of breast cancer. The high versatility and easy modification capabilities have made them widely acceptable among oncologists. They are sometimes developed to target over expressed receptors specific to the breast cancer cells. These vaccines stimulate a cancer patients' immune system to identify and eliminate breast cancer cells. Clinical trials have also shown the efficacy of peptide vaccines in shrinking breast cancer. This has encouraged the oncologists to develop better breast cancer vaccine for patients. The development and deciphering of underlying principle of breast cancer vaccine will improve significantly driven by technological advancement occurred in recent years. Innovative products developed in this way will decrease the development time and will also help in cost arbitrage. Without cost effectiveness it would be difficult for pharmaceutical companies to compete and occupy substantial share in breast cancer market. However, it is expected that the cost of these vaccines would be high at the time of introduction which will subsequently decrease due to availability of other vaccines in same category. It is most likely that the first breast cancer vaccines would be introduced in market in the next 3-5 years period. Clinical trials would be able to come with thoroughly checked version of products under investigation which would be able to provide higher levels of medical care to breast cancer patients. Most of the innovative products are at the final stages of clinical trials which are supposed to clear the targeted end points. Global Breast Cancer Vaccine Clinical Trial Insight Report Highlight: - Global Breast Cancer Vaccine Market Overview - Global Breast Cancer Vaccine Clinical Pipeline by Company, Phase & Country - Mechanism of Breast Cancer Vaccine & Personalized Cancer Vaccines - Detailed Clinical Insight on Breast Cancer Vaccine Pipeline: 35 Vaccines - Majority in PHASE-I Clinical Trial: 12 Vaccines - Highest Clinical Phase is PHASE-III: 2 Vaccines (NeuVax & OBI-822) Key Topics Covered: 1. Global Breast Cancer Vaccine Market Overview 2. Global Breast Cancer Vaccine Market Dynamics 3. Mechanism of Breast Cancer Vaccine 4. Personalized Cancer Vaccines: Progress & Possibilities 5. Global Breast Cancer Vaccine Market Future Prospects 6. Global Breast Cancer Vaccines Pipeline by Phase, Company & Country 7. Suspended & Discontinued Breast Cancer Vaccines Pipeline by Phase, Company & Country 8. Competitive Landscape - AlphaVax - Galena Biopharma - Generex Biotechnology - GlaxoSmithKline - Immune Design - Immunovaccine - Immunovative Therapies - Imugene - TapImmune - ViroMed For more information visit http://www.researchandmarkets.com/research/z2...bal_breast
IMDZ: 25.34 (+1.20), GALE: 1.68 (+0.06), GSK: 47.94 (+1.99)
Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons
PR Newswire - Mon Oct 27, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) today announced two presentations demonstrating that the extent of the immunological response triggered by its novel proprietary cancer immunotherapeutic AE37 vaccine correlated with a reduction of relapse in breast cancer patients. The AE37 cancer vaccine is being developed by the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com). The presentations are being made at the American College of Surgeons Clinical Congress 2014, being held October 26-30, 2014 in San Francisco, CA.
Generex / Antigen Express to Participate in 2014 BIO-Europe® Annual International Partnering Conference
PR Newswire - Thu Oct 23, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 2014 BIO-Europe® Annual International Partnering Conference being held November 3-5 in Frankfurt, Germany.
Generex Announces Publication of Ebola Vaccine White Paper by Antigen Express
PR Newswire - Tue Oct 21, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that its wholly owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), has issued a white paper outlining the advantages of its Ii-Key technology in the development of an effective Ebola vaccine.
Generex Clarifies Utility of Antigen Express Technology for Potential Ebola Vaccine
PR Newswire - Tue Oct 07, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today responded to a recent article posted to the Seeking Alpha website (http://seekingalpha.com/article/2533015-with-ebola-looming-when-will-the-defense-department-get-around-to-generex) regarding the need for an Ebola vaccine and the importance of providing funding for small companies with technologies applicable to such an endeavor. Generex is the parent company of Antigen Express, Inc. (www.antigenexpress.com), which focuses on the development of synthetic peptide vaccines for significant unmet medical needs.
Generex hires Dr Lakshmi P. Kotra for buccal insulin enhancement project
M2 - Wed Oct 01, 6:12AM CDT
Drug delivery company Generex Biotechnology (Other OTC :GNBT) said on Tuesday that it has engaged Dr Lakshmi P. Kotra, B. Pharm(Hons), PhD to provide consultancy, expertise and assistance in the management of its buccal insulin enhancement project.
Generex Announces Engagement of Dr. Lakshmi P. Kotra for Buccal Insulin Enhancement Project
PR Newswire - Tue Sep 30, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it has engaged Dr. Lakshmi P. Kotra, B. Pharm.(Hons), Ph.D., as a consultant to the Company to provide expertise and assistance in the management of the Company's previously announced buccal insulin enhancement project. In this role, Dr. Kotra will work closely with the Company's Senior Scientific Advisor, Dr. James H. Anderson, Jr., MD, and Company management working to increase the insulin bioavailability of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes.
Generex Collaborates with University Health Network for Buccal Insulin Project
PR Newswire - Mon Sep 22, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that it has entered into a collaboration with University Health Network (UHN) pursuant to which UHN's Centre for Molecular Design and Preformulations (CMDP) will spearhead the Company's buccal insulin refinement project. The goal of the project is to increase the insulin bioavailability of Generex Oral-lyn(TM), the Company's proprietary buccal insulin spray product, thereby reducing the number of puffs required to achieve effective prandial metabolic control for patients with diabetes. This research will ensure the product is more attractive to patients and prospective commercialization partners.
Generex / Antigen Express to Participate in BioPharm America(TM) 2014
PR Newswire - Wed Sep 03, 8:15AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced that the Company's wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be participating in the 7th Annual International Partnering Conference BioPharm America(TM) 2014 being held September 22-24 in Boston. The conference is a significant business development forum for companies like Antigen Express, providing access to high-level executives and influential decision makers who attend the forum to liaise with key players in the industry, form partnerships, and evaluate emerging technologies. Antigen Express launched its strategic partnering program at the BIO International Convention in San Diego in June, 2014.
Generex Announces Publication of AE37 Prostate Cancer Vaccine Study
PR Newswire - Wed Aug 06, 8:30AM CDT
Generex Biotechnology Corporation (www.generex.com) (OTCBB:GNBT) today announced publication of a follow-up study from a Phase I clinical trial of the immunotherapeutic agent AE37 in patients with prostate cancer. The study demonstrates an association between a specific immune response generated by AE37 and improved overall survival. The compound is being developed by Antigen Express, Inc. (www.antigenexpress.com), a wholly-owned subsidiary of Generex, for multiple cancer indications.
H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/748t6b/h5n1_infection) has announced the addition of the "H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Johnson & Johnson - Autoimmune Technologies, LLC - GlaxoSmithKline plc - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Generex Biotechnology Corporation - Takeda Pharmaceutical Company Limited - Nanotherapeutics, Inc. - Novartis AG - CEL-SCI Corporation - OPKO Health, Inc. - Hemispherx Biopharma, Inc. - Medicago Inc. - BioDiem Ltd - NanoViricides, Inc. - Medigen Biotechnology Corporation - SIGA Technologies, Inc. - XOMA Corporation - Green Cross Corporation - Antigen Express, Inc. - Adimmune Corporation - TechnoVax, Inc. - Cocrystal Pharma, Inc. - PaxVax - Vivaldi Biosciences Inc. - Aprogen, Inc. - Akshaya Bio Inc. - Gemmus Pharma Inc. For more information visit http://www.researchandmarkets.com/research/74..._infection
CVM: 0.84 (-0.01), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), NNVC: 2.97 (-0.05), SIGA: 1.95 (-0.01), JNJ: 99.62 (+1.18), OPK: 13.80 (-0.28), XOMA: 3.41 (-0.01), NVS: 102.20 (-0.17)
